secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-020615
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Q4 2023 net loss $24.8M; Phase 3 REACH data expected Q4 2024
--------------------------------------------------------------------------------

- Net loss $24.8M in Q4 2023 (vs $26.1M); full-year net loss $97.3M (vs $109.9M).
- Cash, equivalents, and marketable securities $236.2M; cash runway into 2026.
- Phase 3 REACH trial for losmapimod in FSHD on track for topline data in Q4 2024 after enrolling 260 patients.
- Phase 1b PIONEER trial for pociredir in SCD restarted; cohorts evaluating 12 mg and 20 mg daily doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017024020615/0000950170-24-020615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017024020615/fulc-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer